HELP: Cybin Secures $50M Offering Boost!

Dividend Policy & Yield

Helus does not pay any dividend and has no history of shareholder distributions. As a development-stage biotech, all cash is reinvested into R&D. Management’s stated policy is to retain earnings to fund product development and growth, with no expectation of cash dividends in the foreseeable future (cdn.yahoofinance.com). There are no restrictions preventing dividends, but Helus will only consider initiating a dividend if it achieves sustainable profits and cash flow in the future (cdn.yahoofinance.com). Consequently, forward dividend yield is 0%, and metrics like AFFO/FFO are not applicable given the company’s pre-revenue status. Until any future profitability, investors’ only return comes from stock price appreciation, as Helus explicitly warns that it “does not anticipate paying cash dividends… in the foreseeable future” (cdn.yahoofinance.com).

Leverage & Capital Structure

Helus’s capital structure is equity-heavy with minimal debt. As of its last annual report, total liabilities were only ~C$10.1 million versus C$302 million in assets (www.sec.gov). These liabilities consisted mostly of accounts payable (for research and operations) and small lease obligations – no traditional bank debt or bonds outstanding. The company’s debt-to-equity is effectively zero, reflecting a strategy to finance operations through equity raises and strategic instruments rather than loans.

Notably, in mid-2025 Helus (then Cybin) introduced its first significant debt-like financing: a convertible debenture facility. In June 2025, the company entered an agreement to issue up to US$500 million in unsecured convertible debentures, completing an initial $50 million tranche on June 30, 2025 (ir.cybin.com) (ir.cybin.com). These convertible notes carry a 5.5% annual interest rate (prepaid at closing) and can convert to equity at roughly a 30% premium to the prevailing share price (ir.cybin.com) (ir.cybin.com). The remaining $450 M capacity is available for future funding by mutual agreement, providing flexibility but also the potential for considerable dilution if fully utilized. Importantly, Helus has no significant near-term maturities – the convertible’s term spans multiple years (prepayment incurs a premium in year 1 or later (ir.cybin.com)), and there are no bank loans to refinance. This gives the company breathing room to focus on clinical milestones without looming principal repayments. Overall, leverage remains low; even after the $50M debenture, the balance sheet is largely debt-free, with cash far exceeding any interest-bearing liabilities.

Coverage & Liquidity

Given the lack of traditional debt and no dividends, coverage ratios are not meaningful for Helus. The company has no interest expense from bank debt, and the convertible debenture’s interest was prepaid upfront, so current interest coverage (EBIT/interest) isn’t a concern – though notably Helus has negative EBIT due to ongoing R&D spending. In effect, operating losses are being covered by Helus’s cash reserves and new financing, rather than by operating income. For example, in FY2024 Helus’s operations burned roughly C$69 million net cash (operating and investing outflows) while it raised over C$254 million net from financing activities (www.sec.gov). This enabled cash on hand to surge to C$209 million as of March 31, 2024 (www.sec.gov) (www.sec.gov).

The recent $50 M equity offering will further strengthen liquidity. Helus’s cash runway appears ample for the medium term, given prior raises: it added ~$150 M (US) in March 2024 and ~$175 M in late 2025 through sizable share offerings (described below). Indeed, one analysis noted the company “holds more cash than debt… though it has been rapidly burning through cash reserves” (za.investing.com) to advance its trials. Looking ahead, the key coverage question is cash burn – i.e. whether Helus’s cash plus new funding will cover the costly Phase 3 program through data readout in late 2026. The proceeds of the current $50M raise are earmarked to “progress HLP003 and HLP004… and for working capital” (www.barchart.com), which should extend Helus’s operational runway. However, with no product revenue expected until at least 2027+, Helus will remain reliant on its cash reserves and external financing to cover all expenditures. In summary, liquidity is strong now after successive raises, but cash flow coverage of R&D spend is entirely dependent on these financing infusions. Investors should monitor how quickly the cash is consumed by trial costs (Helus itself acknowledges its “rapid” cash burn (za.investing.com)) and whether further raises might be needed before a drug approval.

Valuation

Traditional valuation metrics are challenging for Helus Pharma. The company has no positive earnings (EPS TTM is –$4.30) (uk.finance.yahoo.com) and essentially no revenue, so metrics like P/E or EV/EBITDA are not meaningful. Likewise, P/FFO does not apply. Investors instead value Helus based on its book value and pipeline prospects. As of March 2024 the company’s shareholders’ equity was ~C$292 million (bolstered by large cash holdings from recent financings) (www.sec.gov). Following the 2025 and 2026 capital raises, book equity likely expanded further. At a share price around ~$6–7 in mid-2026, Helus’s market capitalization hovers near $300 million (uk.finance.yahoo.com). This implies a price-to-book ratio on the order of ~1.1–1.3×, indicating the stock trades only modestly above its net asset value (mostly cash and intangibles). In essence, the market is valuing Helus just slightly above the cash on its balance sheet, reflecting skepticism about unproven drug assets.

By contrast, if Helus’s drug candidates succeed, the upside could be significant – a fact not lost on analysts. According to Benzinga, Wall Street’s price targets on HELP range wildly from a low of $8 to a high of $95, with a $51.50 consensus (www.benzinga.com). Such dispersion underscores the speculative nature of valuation here: one bull predicts a multi-bagger outcome (assuming clinical success and sizable market adoption), while another sees limited upside or further dilution (a far more conservative view). Notably, at ~$6 per share, the stock is well below even the midpoint of analyst targets, which suggests potential upside if Helus even partially delivers on its pipeline. Independent assessments concur that the market may be undervaluing Helus’s prospects – InvestingPro’s model indicates the stock is trading below its fair value, hinting at upside (za.investing.com). However, this “upside” exists only if Helus can translate its R&D into approved, revenue-generating products. The current valuation essentially embeds a hefty risk discount: investors are paying mainly for Helus’s cash and IP, with the pipeline’s multi-billion dollar revenue potential heavily discounted for probability of failure. By comparison, peers in the late-stage psychedelic space like COMPASS Pathways and atai Life Sciences also command only a few hundred-million in market cap – a reflection that the market is taking a “wait-and-see” approach to this entire sector’s valuation. For Helus, any tangible clinical win (e.g. positive Phase 3 results or FDA filing) could cause a major upward re-rating, while setbacks would likewise erode the currently modest premium over cash. In summary, Helus’s valuation is a high-stakes bet: the stock is cheap relative to optimistic scenarios, but rightly so given the binary outcomes ahead.

Risks & Red Flags

Helus Pharma faces significant risks and red flags that investors should weigh against its potential:

- Financing & Dilution Risk: Helus’s ambitious clinical programs require continual funding. The company has aggressively diluted shareholders to raise capital – for instance, in March 2024 it issued 348.8 million new shares at ~US$0.43 (pre-consolidation) to raise ~US$150 M (www.sec.gov), and in October 2025 it sold 22.3 million shares at $6.51 to raise another $175 M (za.investing.com). These massive dilutive offerings (followed now by the $50 M offering) have dramatically increased the share count, eroding early shareholders’ ownership. Future dilution remains a core risk: Helus has an at-the-market program authorized for $100 M (www.sahmcapital.com) and even a $450 M unused convertible facility, meaning more shares could be issued if needed. A Simply Wall St analysis encapsulated this risk well: to invest in Helus, one “must believe its psychedelic candidates can become approved, commercial treatments before access to capital or dilution erodes too much of the upside” (www.sahmcapital.com). In other words, Helus is in a race to create value faster than it depletes cash and dilutes equity. If trials face delays or additional funding needs, shareholders could be diluted further or saddled with debt, a red flag for equity value.

- Cash Burn & Going-Concern Risk: Relatedly, Helus’s cash burn rate is very high. The company spends tens of millions annually on R&D, clinical trials, and operations, with no offsetting revenues. While it currently has a substantial cash reserve (post-offerings), that money will be consumed quickly by Phase 3 trial costs, manufacturing scale-up, and a possible commercial launch build-out. If Helus experiences cost overruns or extended trial timelines, it may need to raise capital sooner than expected. A worsening market or lower stock price at that time could make funding more difficult or dilutive. Though Helus has more cash than debt now, it is “rapidly burning” cash (za.investing.com), which raises the risk of eventually hitting a cash crunch. Any hint of insufficient funding to reach key milestones (e.g. Phase 3 completion) would severely impact the stock. This existential reliance on external capital is a constant overhang – a classic high-risk biotech trait.

- Clinical & Regulatory Risk: All of Helus’s potential value hinges on clinical trial success and regulatory approvals that are far from guaranteed. HLP003 (for depression) is only in Phase 3 now, and although earlier Phase 2 data were promising, there is significant risk that pivotal trial results could fail to meet endpoints or reveal safety issues. Similarly, HLP004 is in Phase 2 for anxiety – an indication with high placebo effect and tricky trial design. Any adverse trial outcome or FDA clinical hold would be a major setback. Furthermore, even if trials succeed, regulatory approval is uncertain for novel psychedelic therapies. Helus’s compounds are new (first-of-kind deuterated psychedelic analogs); regulators may require additional studies or post-approval safeguards given the history of psychedelic substances. The timing of approvals could also be slower than the company hopes. Setbacks in the clinic or with regulators are a real possibility, and would likely result in heavy stock declines (and potential asset impairment write-downs of Helus’s C$83 M in goodwill/intangibles).

- Commercial and Market Risk: Helus is still years away from commercialization, yet it aspires to become a fully integrated pharma company. There is risk in its go-to-market execution if and when a product is approved. The company would need to either partner with a larger pharma or build its own sales and marketing infrastructure for a novel psychiatric treatment – a challenging and costly endeavor. Helus’s new CEO, Michael Cola, has big-pharma experience (he helped build Shire’s Vyvanse into a blockbuster) (www.stocktitan.net), indicating the company’s intent to tackle commercialization. However, market adoption of psychedelic-based therapy is unproven. Even if HLP003 gets FDA approval, psychiatrists and payers might be slow to embrace it without robust real-world data. Treatment involves guided psychedelic sessions which may face stigma or logistical hurdles. Thus, revenue ramp-up could disappoint. Pricing and reimbursement are also open questions; if insurers balk at covering psychedelic therapy, the addressable market could be limited despite high unmet need.

- Competition and IP Risk: The psychedelic therapeutics field is increasingly competitive. Helus is not alone – COMPASS Pathways is in Phase 3 with a psilocybin therapy for depression, MindMed and GH Research are advancing LSD/DMT programs, and even big players (via partnerships) are eyeing this space. Some competitors are ahead in certain indications. For example, COMPASS’s psilocybin (COMP360) could potentially reach the market around a similar timeframe, which might reduce first-mover advantage for Helus’s HLP003 in depression. If a competitor’s drug is first to approval or proves more effective/safer, Helus could struggle to gain share. Additionally, Helus must rely on its patent portfolio (100+ patents granted) (www.stocktitan.net) to protect its novel molecules. Any IP challenges or workarounds by competitors could erode future exclusivity. Overall, there is no guarantee Helus will emerge as a winner in what may become a crowded marketplace for psychedelic therapies by the late 2020s.

- Red Flags – Stock Volatility & Share Structure: Helus’s stock has a history of extreme volatility and restructuring. The company’s need to uplist to Nasdaq and maintain compliance led to a likely reverse stock split (share consolidation) around late 2025/early 2026 to boost the share price above the Nasdaq minimum. While this was a necessary move (and the new HELP listing brings more visibility), reverse splits can be red flags, as they often follow steep declines in the stock. Even after consolidation, Helus’s share float remains relatively large, and the stock can swing sharply on news or speculation. Additionally, a single large shareholder (or strategic investor like High Trail via the convertible debenture) could convert debt to equity and potentially sell shares, putting technical pressure on the stock price. The presence of these instruments and warrants from prior financings means the capital structure is complex and could overhang the stock. Investors should be prepared for ongoing dilution events and price volatility as inherent features of Helus’s journey.

In sum, Helus is a high-risk, high-reward story. The company’s red flags – heavy dilution, cash burn, unproven drugs – are typical of developmental biotechs, and any one of these risks (financing shortfall, trial failure, etc.) could seriously impair the investment thesis. Robust risk management (cost control, thorough trial design, active investor communications) will be critical for Helus moving forward.

Open Questions

Finally, several open questions surround Helus Pharma’s trajectory, which current and prospective investors may want to consider:

- Will $50 M Be Enough? The recent $50 million offering certainly extends Helus’s runway, but how far will this war chest go? Management aims to reach the HLP003 Phase 3 data readout by Q4 2026 (www.businesswire.com). Is the current cash (plus $50 M infusion) sufficient to complete that trial and prepare an FDA submission, or will Helus need yet another raise in 2027? The answer hinges on trial costs and whether any unforeseen expenses (additional studies, manufacturing scale-up) arise. Investors will be watching Helus’s quarterly burn rate closely to gauge if/when further funding might be required.

- Convertible Facility: Friend or Foe? Helus has that massive $500 M convertible debenture facility on tap, with $50 M already drawn. An open question is whether Helus will utilize more of this facility going forward. The upside is that it could provide fast capital (potentially up to $450 M remaining) without an immediate equity offering; the downside is it acts like debt and conversion could bring huge dilution at uncertain prices. Will Helus draw additional tranches from this facility to avoid a stock offering, or stick to issuing equity as it has in the past? How High Trail exercises or converts its stake is another unknown – a lot depends on where Helus’s share price goes relative to the conversion thresholds. This strategic decision will impact the future leverage and share count materially.

- Pipeline Prioritization: Helus’s portfolio includes HLP003 (MDD), HLP004 (GAD), HLP005 (preclinical), and other earlier-stage programs. As resources tighten, can Helus afford to advance multiple programs in parallel? Or will it concentrate on the lead indication to ensure success there first? The company’s use of proceeds statement included HLP005 (a preclinical program) (www.barchart.com), suggesting it’s still investing broadly. An open question is whether Helus might trim or partner out some programs to focus its cash on the most promising asset. Similarly, what’s the plan for HLP004 if HLP003’s Phase 3 is successful – will Helus try to develop two CNS drugs simultaneously or stagger them? The allocation of capital across the pipeline will signal management’s priorities and risk appetite.

- Partnership or Solo Commercialization? If Helus achieves positive Phase 3 results, will it seek a partnership with Big Pharma to handle Phase 3b/4 studies, regulatory navigation, and global marketing? Or does Helus intend to go it alone commercially? The hiring of CEO Michael Cola, who has experience launching CNS drugs at large companies (www.stocktitan.net), hints that Helus is preparing for independent commercialization and building a “commercial stage” infrastructure. Going solo could preserve upside but requires significant investment in sales, medical affairs, and distribution capabilities – a challenge for a small company. On the other hand, a deep-pocketed partner could accelerate market penetration but at the cost of sharing profits. The strategy here remains undetermined: management has not publicly ruled out partnerships, and indeed many investors expect that a successful Phase 3 could trigger either a licensing deal or even an acquisition of Helus by a larger pharma looking to enter psychedelics. How (and when) Helus’s board will choose to monetize or commercialize its lead asset is thus an open question with big implications for shareholder value.

- Competitive Landscape and Differentiation: As Helus approaches the finish line for HLP003, what will the competitive landscape look like? By late 2026, Compass Pathways may also have Phase 3 data for psilocybin in depression, and other companies could be in advanced trials. How will Helus differentiate HLP003 from pure psilocybin approaches or newer entries? The company touts advantages like a potentially shorter psychedelic session and 12-week durability of effect (as seen in earlier CYB003 studies) (ir.cybin.com), but will these translate into a compelling marketing edge if a competing therapy is first to market? Moreover, could the FDA require that psychedelic treatments be administered only in specialized centers, limiting scalability? These uncertainties about market positioning, penetration, and real-world use of Helus’s therapies remain unresolved. Investors are keen to understand if Helus’s “second-to-market” strategy (should Compass beat them to approval) would still yield a substantial share, or if being a follower in this space is a disadvantage.

- Long-Term Business Model: In the big picture, can Helus evolve from a clinical-stage venture to a sustainable commercial enterprise? This entails more than getting a drug approved – it means achieving insurance reimbursement, generating consistent revenues, and possibly expanding the pipeline or indications. Questions abound: What peak sales can HLP003 realistically achieve if approved (given only adjunctive use in depression, at least initially)? Will Helus pursue additional indications for its molecules (e.g. PTSD, addiction) to broaden the market? And how will the company utilize its extensive patent estate – might it out-license some IP or develop a second wave of candidates internally? The answers will clarify whether Helus is a one-product story or a platform for multiple CNS innovations.

Each of these open questions underlines that Helus’s story is still in flux. The $50 M offering gives it more time and flexibility to find answers, but only the coming 12–18 months of trial outcomes and strategic choices will truly define Helus Pharma’s fate. Investors should stay tuned to clinical updates, management guidance, and industry developments as this high-risk biotech strives to turn its bold vision (“helping minds heal”) into a viable business reality.

Sources: Helus/Cybin press releases, SEC filings and financial statements, and relevant financial media (www.barchart.com) (cdn.yahoofinance.com) (www.sec.gov) (ir.cybin.com) (ir.cybin.com) (ir.cybin.com) (za.investing.com) (www.sahmcapital.com) (www.stocktitan.net) (www.benzinga.com).